8-K: Silexion Therapeutics Implements 1-for-15 Reverse Stock Split to Maintain Nasdaq Listing

Silexion Therapeutics Corp has enacted a 1-for-15 reverse share split and adjusted its outstanding warrants to comply with Nasdaq's minimum bid price requirement.

Summary

• Silexion Therapeutics Corp (SLXN) completed a 1-for-15 reverse share split, effective after the close of trading on July 28, 2025.
• The company's ordinary shares began trading on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol SLXN at market open on July 29, 2025.
• The reverse share split was approved by shareholders at the reconvened 2025 Annual General Meeting on July 14, 2025, and effected by the Board of Directors on July 28, 2025.
• The authorized share capital remains at $20,000, but now consists of 1,481,482 ordinary shares, with the par value increasing from $0.0009 to $0.0135 per share.
• The number of issued and outstanding ordinary shares has decreased at a 1-for-15 ratio.
• Warrants exercisable for ordinary shares (SLXNW) have been adjusted: each pre-split warrant is now exercisable for 1/15th of an ordinary share.
• The exercise price for each post-split warrant to purchase one whole ordinary share has increased fifteen-fold, from $103.50 to $1,552.50.
• Fractional shares resulting from warrant exercises will be rounded up to the nearest whole number, subject to payment of the full exercise price for the rounded number of shares.

Sentiment

Score: 3

Explanation: The sentiment is largely negative because a reverse stock split is typically a defensive measure to avoid delisting, indicating significant share price weakness and underlying concerns about the company's performance or prospects. While maintaining Nasdaq listing is a positive outcome, the action itself stems from a negative situation.

Positives

• The reverse share split is intended to maintain compliance with Nasdaq's minimum bid price requirement, preventing potential delisting.
• The action aims to adjust the market price of ordinary shares to be within a range of $3.00 to $10.00 or above, potentially improving market perception and liquidity.

Negatives

• A reverse share split typically indicates a significantly low share price, often below exchange minimums, signaling underlying financial or operational challenges.
• The substantial increase in the warrant exercise price to $1,552.50 per share makes warrant exercise significantly more expensive for holders.

Risks

• The company faced a risk of non-compliance with Nasdaq's minimum bid price requirement, which could have led to delisting.
• Despite the reverse split, there is no guarantee that the share price will stabilize or increase to a sustainable level, or that it will remain above Nasdaq's minimum bid price in the long term.

Future Outlook

The company's forward-looking goal for the reverse share split is to maintain compliance with the Nasdaq Global Market or Nasdaq Capital Market's minimum bid price requirement and to initially adjust the market price of the ordinary shares to be within a range of $3.00 to $10.00 or above.

Management Comments

• Ilan Hadar, Chief Executive Officer, signed the report on behalf of Silexion Therapeutics Corp.
• Ms. Mirit Horenshtein Hadar, CFO, is listed as a contact for warrant holders with questions.

Industry Context

Reverse stock splits are a common corporate action undertaken by companies whose stock prices have fallen significantly, often below the minimum bid price required by stock exchanges like Nasdaq. This action aims to artificially inflate the per-share price to avoid delisting, though it does not change the company's underlying market capitalization or fundamental value. Such moves are frequently seen in smaller biotechnology or early-stage companies that may be pre-revenue or facing challenges in clinical development or market adoption.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism for companies to regain compliance with exchange listing requirements, particularly the minimum bid price rule. For example, many small-cap biotech firms, such as those that have experienced clinical trial setbacks or delays in product commercialization, have historically resorted to reverse splits to maintain their Nasdaq listings.
• The 1-for-15 ratio is a significant consolidation, indicating a substantial need to increase the per-share price. While ratios vary, such a high ratio often suggests a prolonged period of low share price performance.
• The adjustment of warrants, including the proportional decrease in shares issuable and the increase in exercise price, is standard practice following a reverse stock split to maintain the economic value of the warrants.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares, but each share will have a proportionately higher price. The total value of their holdings should remain the same immediately after the split, but the action itself often signals underlying issues that could impact future value.
• Warrant Holders: The number of shares they can acquire per warrant decreases, and the exercise price per share increases significantly, making it more expensive to exercise warrants for a whole share.

Next Steps

• Silexion Therapeutics Corp's ordinary shares will continue trading on the Nasdaq Capital Market under the existing ticker symbol SLXN on a split-adjusted basis.
• Warrant holders will need to be aware of the adjusted exercise price and the reduced number of shares issuable per warrant.

Key Dates

Recommendation

The 1-for-15 reverse share split is a strong indicator of severe share price depreciation, likely driven by fundamental business challenges or a lack of positive catalysts. While it temporarily addresses Nasdaq listing compliance, it does not resolve the underlying issues that led to the low share price. Such actions often precede further declines as they can signal a lack of confidence from the market and may not attract new investors. For a seasoned investor, this move suggests significant risk and a 'sell' recommendation to avoid potential further losses, unless there are compelling, unstated positive developments.

Keywords

Reverse Share Split, Warrant Adjustment, Nasdaq Listing Compliance, Corporate Action, Share Consolidation, SLXN, SLXNW, Silexion Therapeutics